Table 1 Backgrounds of patients
Variables | All patients | Survival | Death | p-value |
|---|---|---|---|---|
Subject, n | 68 | 50 | 18 | |
Demographics | ||||
Age, years | 75 (72–80) | 75 (71–80) | 76 (74–80) | 0.42 |
Males, n | 49 (72%) | 37 (74%) | 12 (67%) | 0.56 |
Comorbidities | ||||
Cardiac disease, n | 49 (72%) | 34 (68%) | 15 (83%) | 0.36 |
Respiratory disease, n | 16 (24%) | 12 (24%) | 4 (22%) | 1.00 |
Renal failure, n | 4 (5.9%) | 2 (4.0%) | 2 (11%) | 0.28 |
Malignancy, n | 9 (13%) | 6 (12%) | 3 (17%) | 0.69 |
Antithrombotic therapies | ||||
Antithrombotic therapy, n | 48 (71%) | 33 (66%) | 15 (83%) | 0.23 |
Antiplatelet drugs alone, n | 7 (10%) | 4 (8.0%) | 3 (17%) | 0.37 |
Anticoagulant drugs alone, n | 23 (34%) | 16 (32%) | 7 (39%) | 0.77 |
Antiplatelet and anticoagulant drugs, n | 18 (26%) | 13 (26%) | 5 (28%) | 1.00 |
Etiological diseases of DAH | ||||
Immune disease, n | 6 (8.8%) | 3 (6.0%) | 3 (17%) | 0.33 |
Drug-induced pneumonitis, n | 4 (5.9%) | 3 (6.0%) | 1 (5.6%) | 1.00 |
Heart failure, n | 3 (4.4%) | 1 (2.0%) | 2 (11%) | 0.17 |
Infection, n | 9 (13%) | 5 (10%) | 4 (22%) | 0.23 |
Other disease, n | 9 (13%) | 7 (14%) | 2 (11%) | 1.00 |
Idiopathic, n | 37 (54%) | 31 (62%) | 6 (33%) | 0.053 |